Accuray presents the improved ESTRO 31 TomoTherapy treatment planning system.
new technology VoLO ™ offers greater efficiency and flexibility in the planning of complex treatments, demonstrates the current commitment of Accuray of advance of radiation oncology.
Madrid, may 2012.- Accuray Incorporated, the leading company of radiation oncology, announced last Thursday the availability of technology VoLO ™ for the TomoTherapy ® System, a new system of planning of treatment that takes advantage of advanced graphics processing technology and a new calculation algorithm to improve clinical efficiencyperformance and flexibility in the development of more complex plans of radiation.
The new VoLO solution also includes parallel processing of high speed for the calculation and optimization of dose, based on the Graphics Processing Unit (GPU) technology, a “first” for the treatment of radiation oncology planning, VoLO represents the first use of a new algorithm for calculating Non-Voxel Broad Beam (NVBB) that takes advantage of GPU unprecedented speed and the system of single beam TomoTherapy Systems radiation to develop dose distributions from the perspective of each beam (up to tens of thousands in any given plan) while they pass through the body of the patient. VoLO technology helps physicians create treatment plans highly customized in less time with greater flexibility, increasing the efficiency of the radiation oncology staff. Improvements in technology offer doctors and dosimetristas the tools necessary to work interactively and in real time to develop the best radiation therapy of intensity-modulated (IMRT) for more complex cases.
“GPU technology is finding application in a variety of scientific disciplines and is suitable for radiotherapy.” “GPU Computing helps to facilitate the planning of treatment for computational applications, allowing our physicians and dosimetristas develop plans in less time, increasing the overall production of the Department and maximizing our clinical resources,” said David Westerly, an Assistant Professor in the Department of Radiation Oncology of the University of Colorado School of Medicine. “The use of GPU technology also promotes greater cooperation and flexibility in the planning process of treatments, which in turn ensures that our patients receive the best treatment of radiation and possible cancer care.”
“With VoLO, doctors can create treatment plans for more optimal patients efficiently, a development that will improve the care of the patient and will allow more patients to benefit from TomoTherapy treatments”, said Euan S. Thomson, Ph.d., director general and Chief Executive Officer of Accuray. “The introduction of this advanced treatment planning technology is based on our commitment to continuously improve the performance of the TomoTherapy System while we strengthen our position as a leader in the innovation of radiation oncology”.
About Accuray
Accuray Incorporated, headquartered in Sunnyvale, Calif., is the leading company of Oncology radiation which develops, manufactures and sells innovative and customized treatment solutions that set the standard of care, with the aim of helping patients to live longer and better. The main technologies of the company – the CyberKnife and TomoTherapy – systems are designed to deliver radiosurgery, body esterotáctico radiation therapy, radiation therapy of intensity-modulated, image-guided radiation therapy, and adaptive radiation therapy. To date, 635 systems have been installed at major hospitals around the world.
